The Bottom Line Retatrutide could mark the next chapter in metabolic medicine, an evolution that takes the success of Ozempic and Mounjaro even further
Retatrutide, with its glucagon component that increases energy expenditure, may theoretically influence energy levels differently, but clinical trial data on subjective energy has not yet been published in detail
Why So Many Are Interested in BPC-157 Many of these benefits are still being studied in animals and early-stage trials
Mattei R, Polotow TG, Vardaris CV, Guerra BA, Leite JR, Otton R, Barros MP
For adults, both medications have similar BMI-based eligibility (BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related condition such as hypertension, dyslipidaemia, polycystic ovarian syndrome, or sleep apnoea)
Cytokine suppression profile: Research data documents that KPV produces statistically significant reductions in TNF- (3045%), IL-6 (2540%), and IL-1 (2035%) in inflamed colonic tissue in preclinical models